BioSpace News Archive

The company announced data from Phase I of its Phase I/II placebo-controlled trial of its vaccine with and without Matrix-M adjuvant.

The U.S. government is seeking $11 billion in civil and criminal penalties from Purdue Pharma as the maker of OxyContin winds its way through bankruptcy.

GentiBio focuses on engineered regulatory T-cells (EngTregs) to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.

With a $30 million investment, Versant Ventures launches Matterhorn Biosciences AG, a company developing T cell receptor therapies based on the recent discovery of MR1-restricted T (MRIT) cells that recognize and kill a wide range of tumors of various tissue origins.

Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.

Researchers are developing simpler COVID-19 diagnostic tests for use outside of labs in an effort to make mass testing available, fast and inexpensive.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

According to a warning from federal officials last week, dozens of drug companies, universities and medical device manufacturers owe more than a decade’s worth of data from clinical trials.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 12:35 p.m. EDT. A live webcast of the pre

Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert ® in the U.S. Supported by a U.S. Commercial Team MORRISVILLE, N.C.--( BUSINESS WIRE )-- Bavarian Nordic today announced the initiation of full commercial operations in the U.S. only eight months after completing the acquisition of the manufacturing and global rights to Rabipur ® /RabAvert ® (Rabies Vaccine) and Encepur ® (Tick-Borne Encephalitis Vaccine) from GlaxoSmithKline p